Cibus, Inc. (NASDAQ:CBUS) Short Interest Update

Cibus, Inc. (NASDAQ:CBUS) saw a significant increase in short interest during the month of September. As of September 15th, there was short interest totalling 2,410,000 shares, an increase of 11.6% from the August 31st total of 2,160,000 shares. Currently, 13.7% of the company’s shares are sold short. Based on an average daily volume of 222,700 shares, the short-interest ratio is presently 10.8 days.

Analyst Upgrades and Downgrades

CBUS has been the subject of several analyst reports. Canaccord Genuity Group dropped their price target on shares of Cibus from $21.00 to $20.00 and set a “buy” rating for the company in a research note on Thursday, September 19th. Alliance Global Partners cut their target price on Cibus from $25.00 to $23.50 and set a “buy” rating on the stock in a report on Tuesday, September 24th. Finally, Canaccord Genuity Group upgraded Cibus to a “strong-buy” rating in a research report on Friday, July 19th.

Cibus Price Performance

NASDAQ CBUS traded up $0.21 during mid-day trading on Tuesday, reaching $3.47. 113,369 shares of the stock were exchanged, compared to its average volume of 130,988. The stock has a market cap of $74.76 million, a P/E ratio of -0.18 and a beta of 1.84. Cibus has a one year low of $3.09 and a one year high of $23.18. The stock has a 50 day simple moving average of $6.65 and a 200-day simple moving average of $11.88.

Cibus (NASDAQ:CBUS) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($1.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.81) by ($0.33). Cibus had a negative net margin of 9,856.84% and a negative return on equity of 29.05%. The business had revenue of $0.84 million during the quarter, compared to analyst estimates of $0.44 million. During the same period in the prior year, the firm earned ($3.05) earnings per share. Sell-side analysts anticipate that Cibus will post -3.84 EPS for the current fiscal year.

Institutional Investors Weigh In On Cibus

Hedge funds and other institutional investors have recently modified their holdings of the company. Armistice Capital LLC bought a new position in shares of Cibus in the second quarter valued at $5,083,000. Vanguard Group Inc. grew its stake in shares of Cibus by 3.7% in the 1st quarter. Vanguard Group Inc. now owns 721,945 shares of the company’s stock worth $16,215,000 after acquiring an additional 26,017 shares in the last quarter. Rhumbline Advisers purchased a new stake in shares of Cibus in the second quarter valued at about $221,000. FineMark National Bank & Trust lifted its position in shares of Cibus by 24.3% during the second quarter. FineMark National Bank & Trust now owns 20,488 shares of the company’s stock valued at $202,000 after purchasing an additional 4,000 shares in the last quarter. Finally, Bank of New York Mellon Corp purchased a new position in Cibus during the second quarter worth about $529,000. Institutional investors own 33.81% of the company’s stock.

About Cibus

Cibus, Inc, a agricultural biotechnology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases.